180 min. All reactions were conducted in 100 l of 10 mM Hepes (pH 7.5) at 37°C. Cleavage products were analyzed with a Waters high-performance liquid chromatograph and DEAE column using a gradient elution of 50 mM ammonium phosphate (pH 5.2) to 450 mM ammonium phosphate (pH 5.7) (6). PKCI hydrolysis reactions were conducted as above with ADP, AppA, and ATP as substrates. AppA hydrolysis was qualitatively observed for PKCI, as was 7-methyguanosine 5Ј-triphospho-5Ј-adenosine and Ap 5 A hydrolysis for FHIT.
residues 14 to 126. Occupancies for the ␣ and ␤ tungstate molecules refined to 0.50 and 0.54, respectively, for PKCI and to 0.47 for FHIT. 12. Vanadate and molybdate pentacovalent metal sites were identified in structures of chloroperoxidase, rat acid phosphatase, bovine low-molecular weight phosphotyrosyl phosphatase, ribonuclease A, and a vanadate-ADP transition-state complex of S1 myosin [B. Borah et al., Biochemistry 24, 2058 (1985 ; Y. Lindqvist, G. Schneider, P. Vihko, Eur. J. Biochem. 221, 139 (1994) ; A. Messerschmidt and R. Wever, Proc. Natl. Acad. Sci. U.S.A. 93, 392 (1996) ; C. A. Smith and I. Rayment, Biochemistry 35, 5404 (1996) ; A. Wlodawer, M. Miller, L. Sjolin, Proc. Natl. Acad. Sci. U.S.A. 80, 3628 (1983) ; M. Zhang, M. Zhou, R. L. Van Etten, C. V. Stauffacher, Biochemistry 36, 15 (1997) ]. The active sites of PKCI and FHIT share several structural similarities and characteristics with protein phosphatases, particularly rat acid phosphatase. A search of the smallmolecule database revealed a pentacovalent tungstate structure with similar characteristics to those observed in our enzyme complex [I. Feinstein-Jaffe, J. C. Dewan, R. R. Schrock, Organometallics 4, 1189 Organometallics 4, (1985 ]. The bond lengths and angles observed in our crystal structures are in agreement with those observed in several other tungsten-containing molecules found in the database. We know of no reported protein structure that describes a similar pentacovalent tungstate complex.
13. L. Holm and C. Sander, Structure 15, 165 (1997); Trends Biochem. Sci. 22, 116 (1997 Graphics 11, 134 (1993 (2) . KSHV DNA is present in all KS biopsies, and antibodies to this virus are detectable mainly in those with KS or at risk of developing KS (3) . These data, and previous epidemiological data indicating that an infectious agent is involved in KS pathogenesis (4), suggest that KSHV is likely to play a central role in KS tumorigenesis. In KS biopsies, KSHV is present in most of the tumor cells (so-called spindle cells) and in endothelial cells (5) . Although it appears that KSHV gene expression in most of these cells is restricted to latent genes (5), a proportion of endothelial and spindle cells in KS lesions harbor hundreds of viral particles, suggesting that lytic viral infection may be necessary to drive KS lesion formation (6) and the vMIPs are expressed in KS lesions (7) . KSHV is also etiologically linked to multicentric Castleman's disease (MCD), a polyclonal lymphoproliferation associated with prominent vascularity (8) .
Sequencing of the KSHV genome has demonstrated colinearity and similarity with the gamma-oncogenic viruses Epstein-Barr virus (EBV) and herpesvirus saimiri (HVS) (9) . However, unique among known human herpesviruses, KSHV encodes two genes whose products show sequence similarity to the human CC chemokine family, with highest similarity to macrophage inflammatory protein-1␣ (MIP-1␣) and RANTES: vMIP-I [open reading frame (ORF) K6] exhibits 37.9% amino acid sequence identity and vMIP-II (ORF K4) 41.1% amino acid identity to MIP-1␣ (10) . The amino acid identity between vMIP-I and vMIP-II is 48%, and they are more closely related to each other phylogenetically than to cellular chemokines, suggesting that they have evolved by gene duplication within the virus genome rather than by independent acquisition from the host genome. A third KSHV ORF (K4.1) is also related to the CC chemokine family, but this gene is more distantly related and probably derived independently from another member of the CC chemokine family (9, 11) . Both vMIP-I and vMIP-2 are expressed in latently infected lymphoma cells, and their expression is induced by phorbol esters (10) .
Chemoattractant cytokines (chemokines) and their receptors play a fundamental role in leukocyte migration and activation and in hematopoiesis (12) . The finding that chemokine receptors act as cofactors for HIV-1 entry into CD4 ϩ cells and that the CC chemokines (MIP-1␣, MIP-1␤, RANTES, and eotaxin) can suppress some strains of HIV replication in peripheral blood mononuclear cells (PBMCs) and chemokine receptor-transfected cell lines has intensified interest in these proteins (13) . vMIP-I can inhibit infection of some primary non-syncytium-inducing (NSI) HIV strains when cotransfected with CCR5, the recently identified coreceptor for NSI HIV-1 strains (10). We generated synthetic proteins (14) of vMIP-I and vMIP-II and assessed their capacity to inhibit HIV infection, induce calcium mobilization, and induce angiogenesis.
We investigated whether vMIP-I and vMIP-II can suppress HIV-1 replication in U87/CD4 cells (a human glioma cell line) expressing HIV-1 coreceptors and in primary PBMCs (15) . To define which chemokine receptors were most important for inhibition of HIV-1 infection by the vMIPs, we tested U87/CD4 cells stably expressing either CXCR4, CCR3, or CCR5 with the NSI strains SL-2 and SF162 and the dualtropic syncytium-inducing (SI) strains 89.6 and 2028. SL-2 and SF162 are primary NSI, macrophage-tropic strains that use the RANTES, MIP-1␣, and MIP-1␤ receptor CCR5 to gain entry into CD4 ϩ cells. Strains 89.6 and 2028 are SI dual-tropic and can use CXCR4 and CCR3 in addition to CCR5 for entry. CD4-independent infection of an HIV-2 strain, ROD/B, on U87 cells expressing CXCR4 but not CD4 was also examined (16). Whereas modest levels of inhibition were observed with vMIP-II on infection of dual-tropic HIV-1 strains by way of CCR5 and CXCR4 as well as on HIV-2 ROD/B by way of CXCR4 (17), vMIP-II potently inhibited both 89.6 and 2028 infection, with geater than 95% inhibition at 200 nM on cells stably expressing CCR3 (Fig. 1A) . No significant blocking of HIV infection by way of CCR3, CCR5, or CXCR4 on U87/CD4 cells by vMIP-I was observed ( Fig. 1A ) (17). These results suggest that vMIP-II binds predominantly to CCR3, rather than CXCR4 or CCR5. Alternatively, HIV-1 infection by way of CCR3 may be especially sensitive to chemokine inhibition.
We next tested whether vMIP-I or vMIP-II inhibited HIV-1 infection of PBMCs. Strains 89.6 and SL-2 were used in these studies. Both vMIP-I and vMIP-II partially inhibited SL-2 infection of PBMCs (Fig.  1B) . Whereas RANTES reduced SL-2 infection of PBMCs by more than 98% at 12.5 nM, vMIP-I and vMIP-II were much less efficient, blocking infection by ϳ80% and 40%, respectively, at 100 nM. No substantial inhibition of 89.6 infection was observed. vMIP-I inhibited the CCR5-using SL-2 strain on PBMCs but not on CCR5 ϩ U87/ CD4 cells. CCR5, however, is likely to be expressed at substantially lower levels on PBMCs than on cell lines such as U87/CD4. This difference may explain such differential cell type-dependent sensitivity to chemokine inhibition.
Because the HIV inhibition studies indicated that vMIP-II binds predominantly to CCR3, the eotaxin receptor, we investigated the potential of the vMIPs to act as agonists on CCR3. Because CCR3 is expressed predominantly on eosinophils (18), we used an in vitro human eosinophil activation assay that measures intracellular Ca 2ϩ mobilization (19). vMIP-II, like eotaxin, was a potent activator of human eosinophils and was more active than MIP-1␣ or RANTES ( Fig. 2A) . In comparison, vMIP-II had no effect on Ca 2ϩ flux in human neutrophils, whereas the CXC chemokines interleukin-8 (IL-8) and GRO␣ were potent agonists ( Fig. 2A) . Despite the sequence similarities between vMIP-I and vMIP-II, vMIP-I was inactive on both eosinophils and neutrophils. We therefore examined whether vMIPs function as receptor antagonists on eosinophils and neutrophils, as has been demonstrated for synthetic NH 2 -terminal variants of CC (for example, Met-RANTES) and CXC (for example, IL-8 1Ϫ69 ) chemokines (20) . vMIP-I had no inhibitory effect on the response of eosino- Whereas CCR3 is the predominant chemokine receptor through which eotaxin, RANTES, and other CC chemokines activate eosinophils (18), RANTES and MIP-1␣ can use CCR1 (21) , which is also expressed on eosinophils. To determine the receptor usage by vMIP-II on eosinophils, we performed desensitization studies. vMIP-II exhibited complete cross-desensitization with eotaxin, partial desensitization with RANTES, and no desensitization with MIP-1␣ (Fig. 2B) , providing functional evidence that vMIP-II binds to CCR3 on eosinophils.
To show that vMIP-II can chemoattract eosinophils, we performed an in vitro chemotaxis assay (22) . vMIP-II, but not vMIP-I, was chemotactic for human eosinophils (Fig. 3) . This activity of vMIP-II was comparable to that of eotaxin, which correlates with the activity to induce Ca 2ϩ mobilization ( Fig. 2A) .
Although angiogenesis is central in the pathology of KS and prominent in MCD, the mechanisms by which KSHV induces new blood vessel formation are not known. Angiogenesis is a complex process involving chemotactic migration and proliferation of endothelial cells, followed by lumen formation and functional maturation of the endothelium (23) . Often it is associated with the presence of activated inflammatory cells. Apart from their potent biological effects on leukocytes, some members of the chemokine family have been shown to have a direct effect on blood vessel formation. Within the CXC chemokine family, proteins containing the NH 2 -terminal Glu-Leu-Arg (ELR) amino acid sequence motif such as IL-8 are angiogenic factors, whereas non-ELR-containing proteins including IP-10 are angiostatic (24) . To our knowledge, there is no information on the angiogenic ability of CC chemokines. We therefore examined the potential of vMIP-I and vMIP-II as mediators of angiogenesis in the chick chorioallantoic membrane (CAM), which is a standard in ovo assay to investigate angiogenic function (25, 26) .
Angiogenic responses were observed and photographed 3 days after implantation of a methylcellulose disk containing test samples onto CAM. Most eggs implanted with vMIP-I or vMIP-II showed a clear angiogenic response. The positive controls used, vascular endothelial growth factor (VEGF) and phorbol 12-myristate 13-acetate (TPA), also induced angiogenesis as expected (Fig. 4 and Table 1 ). In contrast, cellular MIP-1␣ and RANTES failed to induce angiogenesis in most eggs, and the few positive responses recorded were not as prominent as those for vMIPs. The potency of vMIPs to induce angiogenesis in chick embryos was demonstrated by clear angiogenic responses in some eggs at doses as low as 0.05 g, in contrast to poor induction by human CC chemokines at 0.25 g. Although it is difficult to interpret a comparison of angiogenic activity between chemically synthesized and recombinant proteins, the activity of the vMIPs was not as potent as that of VEGF, but more potent in the CAM assay than that of the ELR-CXC chemokine IL-8 (Table 1) . Preliminary results also indicate that eotaxin is not an inducer of angiogenesis in CAM. The finding that KSHV-encoded chemokines can induce new blood vessel formation in the chick CAM is intriguing and could have important implications for the role of KSHV in KS and MCD development.
Our results demonstrate that the vMIPs are biologically active: (i) vMIP-II binds predominantly to CCR3, resulting in potent inhibition of HIV entry by way of this receptor and activation and chemotaxis of (10), these viral chemokines may affect HIV pathogenesis. vMIP-II inhibition of HIV infection by way of CCR3 is potent. This result is consistent with the report in which only vMIP-II was studied with a single HIV-1 strain (27) . CCR3 is one of the main receptors for HIV-1 entry into microglia, and an antibody to CCR3 can inhibit HIV-1 infection of microglia (28) . Patients with KS or high KSHV viral load, or both, may be less likely to develop HIV-related dementias. The potent agonistic activity of vMIP-II for eosinophils contrasts with its antagonistic function shown in other cell systems (27) . Although previous studies have shown that HIV Tat is angiogenic (2), this protein does not play a role in the pathogenesis of non-AIDS KS (for example, classic, African endemic, and posttransplant KS). In contrast, KSHV is present at high levels in all epidemiologic types of KS, and the demonstration of angiogenesis induced by these viral-encoded proteins is the first in vivo indication that KSHVencoded proteins have the potential to directly induce angiogenesis. Although it is unlikely that these viral chemokines are solely responsible for the marked vascularity seen in KSHV-associated tumors, they could contribute with other angiogenic factors involved in KS spindle cell growth or MCD development-for example, VEGF, basic fibroblast growth factor and IL-6 (2, 29) . ‡Scores of 1, 0.5, and 0 were counted for (ϩ), (Ϯ), and (Ϫ) results, respectively. Percent maximum score is the division of the score by the embryo number.
§A CXC ELR-containing chemokine.
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ing IL-2 and chemokine. Supernatants were harvested on day 9 and assayed for p24 levels.On U87/CD4 cells, virus infectivity was assessed by a focus-forming assay as described [G. Simmons et al., Science 276, 276 (1997) ]. Briefly, for viruses using more than one coreceptor, focus-forming units (FFUs) were assessed separately for each appropriate coreceptor expressing U87/CD4 cell type. Cells were seeded into 48-well trays at 1 ϫ 10 4 cells per well overnight. The cells were then treated for 30 min at 37°C with appropriate concentrations of chemokine in 75 l. One hundred FFUs of each virus in 75 l were added and incubated for 3 hours at 37°C. The cells were then washed three times, and 500 l of medium containing the appropriate chemokine at the correct concentration was added. After 5 days the cells were fixed for 10 min in cold acetone:methanol (1:1) and immunostained for in situ p24 as described [Á . McKnight, P. R. Clapham, R. A. Weiss, Virology 201, 8 (1994) ]. Standard errors were estimated from duplicate wells, and the results (Fig. 1) are representative of three separate experiments. 16. M. J. Endres et al., Cell 87, 745 (1996) ; J. D. Reeves et al., Virology 231, 130 (1997 Ponath et al., J. Exp. Med. 183, 2437 ; B. L. Daugherty et al., ibid., p. 2349. 19 . Human eosinophils and neutrophils were isolated from the peripheral blood of healthy volunteers as described [P. J. Jose et al., J. Exp. Med. 179, 881 (1994) ]. Briefly, neutrophils (Ͼ95% purity, contaminating cells being a mixture of eosinophils and mononuclear cells) were separated from red blood cells and mononuclear cells by sequential dextran sedimentation and Percoll-plasma density centrifugation. Eosinophils (Ͼ98% purity, contaminating cells being mononuclear cells) were isolated from healthy atopic individuals as described above for neutrophils followed by immunomagnetic separation of the eosinophils from the neutrophils with anti-CD16 microbeads as described (32) . Calcium mobilization in purified neutrophils and eosinophils was measured as described (32) . Briefly, purified neutrophils or eosinophils were incubated with fura-2 acetoxy-methyl ester (1 to 2.5 M), washed three times in 10 mM PBS (without Ca 2ϩ or Mg 2ϩ ) ϩ 0.1% bovine serum albumin (BSA) (200g, 8 min) , and resuspended at 2 ϫ 10 6 cells/ml in 10 mM PBS (without Ca 2ϩ or Mg 2ϩ ) ϩ 0.25% BSA ϩ 10 mM Hepes ϩ 10 mM glucose. Aliquots of cells were placed in quartz cuvettes, and the external Ca 2ϩ concentration was adjusted to 1 mM with CaCl 2 . Changes in fluorescence were measured at 37°C by means of a fluorescence spectrophotometer at excitation wavelengths of 340 and 380 nm and an emission wavelength 510 nm. Intracellular Ca 2ϩ concentration [Ca 2ϩ ] i was calculated with the ratio of the two fluorescence readings and a dissociation constant for Ca 2ϩ at 37°C of 224 nM. In experiments designed to investigate desensitization between agonists, the first agonist (the desensitizing agonist) was added after 50 s and the second agonist added 150 s later.
The caspase-3 (CPP32, apopain, YAMA) family of cysteinyl proteases has been implicated as key mediators of apoptosis in mammalian cells. Gelsolin was identified as a substrate for caspase-3 by screening the translation products of small complementary DNA pools for sensitivity to cleavage by caspase-3. Gelsolin was cleaved in vivo in a caspase-dependent manner in cells stimulated by Fas. Caspase-cleaved gelsolin severed actin filaments in vitro in a Ca 2ϩ -independent manner. Expression of the gelsolin cleavage product in multiple cell types caused the cells to round up, detach from the plate, and undergo nuclear fragmentation. Neutrophils isolated from mice lacking gelsolin had delayed onset of both blebbing and DNA fragmentation, following apoptosis induction, compared with wild-type neutrophils. Thus, cleaved gelsolin may be one physiological effector of morphologic change during apoptosis.
A conserved family of aspartate-specific cysteinyl proteases (caspases) has been identified as critical mediators of apoptosis in Caenorhabditis elegans and mammals (1, 2) . Although multiple protein substrates of caspases have been found, the functional significance of the substrates is poorly understood (3). We reasoned that an unbiased approach to determine proteins that were the best substrates of caspase-3 in vitro would yield a physiologically relevant substrate. Therefore, we constructed a protein library by translating a murine embryo cDNA library in vitro (4) and tested the translated proteins for their sensitivity to caspase-3 cleavage. To facilitate screening, we separated the cDNAs into small pools before in vitro translation and incorporated [ 35 S]methionine into the translation mix to
